Thalidomide-induced vascular defect during the development of zebrafish embryos
Concentration . | Dorsal artery presence, % (no.) . | Dorsal artery absence, % (no.) . | No. embryos . |
|---|---|---|---|
| Thalidomide | |||
| Control | 100 (250) | 0 (0) | 250 |
| 100 μM | 100 (240) | 0 (0) | 240 |
| 200 μM | 89 (212) | 11 (27) | 239 |
| 400 μM | 41 (147) | 59 (210) | 357 |
| 800 μM | 7 (49) | 93 (641) | 690 |
| C2-ceramide | |||
| Control | 100 (250) | 0 (0) | 250 |
| 2.5 μM | 80 (187) | 20 (47) | 234 |
| 5.0 μM | 48 (118) | 52 (127) | 245 |
| 10 μM | 27 (95) | 73 (256) | 351 |
| 20 μM | 12 (54) | 88 (397) | 451 |
| 40 μM | 0 (0) | 100 (535) | 535 |
Concentration . | Dorsal artery presence, % (no.) . | Dorsal artery absence, % (no.) . | No. embryos . |
|---|---|---|---|
| Thalidomide | |||
| Control | 100 (250) | 0 (0) | 250 |
| 100 μM | 100 (240) | 0 (0) | 240 |
| 200 μM | 89 (212) | 11 (27) | 239 |
| 400 μM | 41 (147) | 59 (210) | 357 |
| 800 μM | 7 (49) | 93 (641) | 690 |
| C2-ceramide | |||
| Control | 100 (250) | 0 (0) | 250 |
| 2.5 μM | 80 (187) | 20 (47) | 234 |
| 5.0 μM | 48 (118) | 52 (127) | 245 |
| 10 μM | 27 (95) | 73 (256) | 351 |
| 20 μM | 12 (54) | 88 (397) | 451 |
| 40 μM | 0 (0) | 100 (535) | 535 |
Zebrafish embryos were treated at 75% epiboly stage (8 hpf) with various concentrations of thalidomide or C2-ceramide, and then the defect of dorsal artery was determined by assessing the loss of blood flow under microscopy at the 48-hpf stage.